R
Raymond Thertulien
Researcher at University of Arkansas for Medical Sciences
Publications - 32
Citations - 1718
Raymond Thertulien is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Transplantation & Multiple myeloma. The author has an hindex of 14, co-authored 31 publications receiving 1668 citations. Previous affiliations of Raymond Thertulien include Boehringer Ingelheim.
Papers
More filters
Journal ArticleDOI
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
Bart Barlogie,Guido Tricot,Elias Anaissie,John D. Shaughnessy,Erik Rasmussen,Frits van Rhee,Athanasios Fassas,Maurizio Zangari,Klaus Hollmig,Mauricio Pineda-Roman,Choon Kee Lee,Giampaolo Talamo,Raymond Thertulien,Elias Kiwan,Somashekar G. Krishna,Michele Fox,John Crowley +16 more
TL;DR: When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival.
Journal ArticleDOI
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Maurizio Zangari,Bart Barlogie,Elias Anaissie,Fariba Saghafifar,Paul Eddlemon,Joth Jacobson,Choon Kee Lee,Raymond Thertulien,Giampaolo Talamo,Teri Thomas,Frits van Rhee,Athanasios Fassas,Louis M. Fink,Guido Tricot +13 more
TL;DR: The experience, although not based on a randomized study, suggests that the excess frequency of thrombosis in patients treated with chemotherapy and thalidomide can be safely reduced by the prophylactic use of LMWH.
Journal ArticleDOI
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
Choon Kee Lee,Maurizio Zangari,Bart Barlogie,A. Fassas,F. van Rhee,Raymond Thertulien,Giampaolo Talamo,Firas Muwalla,Elias Anaissie,Klaus Hollmig,Guido Tricot +10 more
TL;DR: The data suggest that significant renal failure can be reversible and AT should be considered early in the disease course, and the role of high-dose melphalan and autologous transplant in reversing dialysis-dependent renal failure is evaluated.
Journal ArticleDOI
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Maurizio Zangari,Bart Barlogie,Raymond Thertulien,Joth Jacobson,Paul Eddleman,Louis M. Fink,Athanasios Fassas,Frits van Rhee,Giampaolo Talamo,Choon Kee Lee,Guido Tricot +10 more
TL;DR: The development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features, and the combination of thalidomide with chemotherapy including doxorubicin was associated with the highest odds ratio for DVT.
Journal ArticleDOI
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.
Marisa H. Miceli,Li Dong,Monica Grazziutti,A. Fassas,Raymond Thertulien,F. van Rhee,Bart Barlogie,Elias Anaissie +7 more
TL;DR: Increased pre-transplant BMIS and smoking are significant predictors of severe infection after myeloablative chemotherapy followed by ASCT in myeloma patients.